2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) on August 5, 2026, making it the first influenza vaccine based on messenger RNA (mRNA) technology. The pivotal FLUENT phase 3 trial randomized more than 40,000 adults aged 50 years and older to mFlusiva or a licensed standard-dose influenza vaccine and found 26.6% relative efficacy against confirmed influenza-like illness compared with the standard-dose vaccine. Traditional approval applies to adults aged 50 through 64 years, while the indication for adults 65 years and older received accelerated approval and requires confirmatory evidence to verify clinical benefit. The platform is particularly interesting for influenza because mRNA manufacturing does not depend on propagating vaccine virus in eggs and could eventually allow production to begin closer to the upcoming influenza season. That flexibility could reduce the time between strain selection and manufacturing, although the current approval does not establish that mFlusiva will consistently achieve better strain matching or greater effectiveness across future influenza seasons. Reactogenicity was higher than with the standard-dose comparator, particularly injection-site pain, fatigue, headache, and myalgia, and patients should be counseled about these expected short-term effects. Serious adverse events occurred at similar rates between groups, with few considered related to vaccination. The FDA indication covers prevention of influenza caused by represented influenza A subtypes and influenza B in adults 50 and older. For physicians, mFlusiva introduces a new vaccine platform with superior efficacy to a standard-dose comparator in FLUENT, while postmarketing evidence in older adults and experience across multiple influenza seasons will determine the magnitude of its practical advantage.

Ecopipam cuts Tourette syndrome relapse risk by 53% in pediatric trial

Tourette syndrome remains difficult to treat pharmacologically because meaningful tic reduction must be balanced against adverse effects that can limit long-term therapy, particularly in children. On August 19, 2026, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for ecopipam and granted priority review for pediatric Tourette syndrome. Ecopipam is an investigational selective dopamine D1 receptor antagonist, providing a mechanism distinct from treatments that primarily target dopamine D2 receptors. In the phase 2b D1AMOND trial, pediatric patients receiving ecopipam experienced statistically significant and clinically meaningful improvement in tic severity compared with placebo after 12 weeks. A subsequent phase 3 randomized withdrawal trial enrolled 216 participants and found that pediatric responders who continued ecopipam had a 53% lower relapse risk than those transitioned to placebo during the randomized period. Across clinical studies, investigators did not identify clinically meaningful changes in weight, metabolic measures, or assessments of drug-induced movement disorders. These findings make the D1-selective mechanism clinically interesting, although longer-term evidence will be necessary to determine whether its tolerability advantages persist with broader use. The FDA has assigned a target action date in late first-quarter 2027, and the indication under review is specifically for pediatric patients. If approved, ecopipam could provide clinicians with a mechanistically distinct option for children with functionally impairing tics while avoiding the assumption that a novel dopamine target automatically translates into superior long-term tolerability.

Daraxonrasib nearly doubles survival in metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) on August 26, 2026, introducing the first-in-class RAS inhibitor for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Daraxonrasib is an oral agent that targets multiple forms of RAS, a family of proteins that drives tumor growth in most pancreatic adenocarcinomas and has historically been difficult to target pharmacologically. Approval was supported by RASolute 302, a randomized, open-label, multicenter trial involving 500 patients with previously treated metastatic disease. Median overall survival reached 13.2 months with daraxonrasib compared with 6.7 months with standard chemotherapy, corresponding to a hazard ratio of 0.40. Median progression-free survival was also longer at 7.2 versus 3.6 months, while the objective response rate was 30% with daraxonrasib compared with 11% with chemotherapy. The magnitude of benefit is notable in metastatic pancreatic adenocarcinoma, a disease in which therapeutic progress has historically been incremental and survival after progression remains limited. Daraxonrasib is taken once daily, with common adverse effects including rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. The prescribing information also includes precautions for gastrointestinal perforation, interstitial lung disease or pneumonitis, and other potentially serious toxicities that require monitoring. For oncologists, the approval is significant not simply because another pancreatic cancer therapy is available, but because direct pharmacologic targeting of RAS has now produced a substantial randomized survival advantage in one of oncology’s most treatment-resistant malignancies.

Brepocitinib improves muscle and skin disease in adult dermatomyositis

The U.S. Food and Drug Administration (FDA) approved Lisraya (brepocitinib) on August 27, 2026 as the first oral treatment specifically indicated for adults with dermatomyositis. The approval is clinically notable because patients with this rare autoimmune disease have historically relied heavily on corticosteroids and immunosuppressive therapies often used off-label rather than treatments developed and approved specifically for dermatomyositis. Brepocitinib is a once-daily oral Janus kinase and tyrosine kinase 2 (JAK/TYK2) inhibitor designed to suppress signaling pathways involved in the inflammatory response affecting muscle and skin. Efficacy was evaluated in a phase 3 randomized, double-blind, placebo-controlled trial involving 241 adults treated for 52 weeks. Patients receiving 30 mg of brepocitinib achieved a greater mean Total Improvement Score than those receiving placebo, reflecting improvement across muscle strength, physical function, skin and other disease activity, muscle enzymes, and physician and patient assessments. Treated patients also demonstrated improvements in physical function and skin disease activity and were more likely to reduce corticosteroid use by week 48. Common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea. Lisraya carries a boxed warning addressing serious infections, malignancy, major adverse cardiovascular events, thrombosis, and increased all-cause mortality associated with this therapeutic class. For rheumatologists and dermatologists, the approval adds a disease-specific oral option with phase 3 evidence across both muscular and cutaneous manifestations, while its safety profile means patient selection and monitoring will remain central to its use.